Alembic Pharma successfully completes USFDA inspection for Panelav facility

Vadodara: Alembic Pharma has announced that the Company has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Oral Solid Formulation Facility (F-I) located at Panelav.

This was a scheduled GMP inspection and was successfully completed without any Form 483 observation.

The inspection was conducted from 17th July, 2024 to 26th July, 2024.

Medical Dialogues team had earlier reported that the Company had received an Establishment Inspection Report (EIR) from the US FDA for the inspection carried out at the Oncology (Injectable and Oral Solid) Formulation Facility (F-2) at Panelav.

Read also: Alembic Pharma gets USFDA EIR for Panelav Oncology formulation facility

Headquartered in Vadodara, Gujarat, Alembic Pharmaceuticals Limited is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities. The company was founded in 1907. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.